Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514",
  "action": "support",
  "content": "I notice that your message mentions \"HYPOTHESES: [MAX TOOL ROUNDS REACHED]\" but doesn't actually include the specific hypotheses you'd like me to assess. It seems like there may have been a truncation or system limitation that prevented the hypotheses from being displayed.\n\nCould you please provide the specific hypotheses you'd like me to evaluate for practical feasibility? Once you share them, I'll conduct a comprehensive assessment for each one, including:\n\n## For Each Hypothesis:\n\n**1. Druggability Assessment:**\n- Target accessibility and binding sites\n- Chemical matter and compound classes\n- Structure-activity relationships\n\n**2. Existing Compounds & Clinical Evidence:**\n- Tool compounds and their properties\n- Clinical candidates in development\n- Specific drug names and trial IDs\n\n**3. Competitive Landscape:**\n- Companies working in this space\n- Pipeline assets and development stage\n- Patent landscape\n\n**4. Safety Concerns:**\n- Known toxicities and off-targets\n- Mechanism-based risks\n- Clinical safety data\n\n**5. Cost & Timeline Estimates:**\n- Preclinical development costs\n- Clinical development timeline\n- Regulatory pathway considerations\n\nPlease share the hypotheses you'd like me to analyze, and I'll use the available research tools to provide a thorough, evidence-based feasibility assessment with specific citations, drug names, trial IDs, and company information where relevant.",
  "tokens_used": "351",
  "persona_id": "persona-domain_expert"
}